Lupin Management

Management criteria checks 3/4

Lupin's CEO is Vinita Gupta, appointed in Sep 2013, has a tenure of 10.67 years. total yearly compensation is ₹109.20M, comprised of 71.7% salary and 28.3% bonuses, including company stock and options. directly owns 0.072% of the company’s shares, worth ₹538.74M. The average tenure of the management team and the board of directors is 3.3 years and 4.2 years respectively.

Key information

Vinita Gupta

Chief executive officer

₹109.2m

Total compensation

CEO salary percentage	71.7%
CEO tenure	10.7yrs
CEO ownership	0.07%
Management average tenure	3.3yrs
Board average tenure	4.2yrs

Recent management updates

Recent updates

Investor Optimism Abounds Lupin Limited (NSE:LUPIN) But Growth Is Lacking

Apr 20

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Mar 03

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 10

CEO Compensation Analysis

How has Vinita Gupta's remuneration changed compared to Lupin's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	₹18b
Sep 30 2023	n/a	n/a	₹13b
Jun 30 2023	n/a	n/a	₹10b
Mar 31 2023	₹109m	₹78m	₹4b
Dec 31 2022	n/a	n/a	-₹3b
Sep 30 2022	n/a	n/a	₹682m
Jun 30 2022	n/a	n/a	-₹22b
Mar 31 2022	₹145m	₹145m	-₹15b
Dec 31 2021	n/a	n/a	-₹5b
Sep 30 2021	n/a	n/a	-₹7b
Jun 30 2021	n/a	n/a	₹17b
Mar 31 2021	₹128m	₹92m	₹12b
Dec 31 2020	n/a	n/a	₹11b
Sep 30 2020	n/a	n/a	-₹2b
Jun 30 2020	n/a	n/a	-₹6b
Mar 31 2020	₹128m	₹93m	-₹4b
Dec 31 2019	n/a	n/a	-₹4b
Sep 30 2019	n/a	n/a	₹3b
Jun 30 2019	n/a	n/a	₹7b
Mar 31 2019	₹15m	₹49m	₹5b
Dec 31 2018	n/a	n/a	-₹5b
Sep 30 2018	n/a	n/a	-₹931m
Jun 30 2018	n/a	n/a	₹960m
Mar 31 2018	₹172m	₹123m	₹3b

Compensation vs Market: Vinita's total compensation ($USD1.31M) is above average for companies of similar size in the Indian market ($USD572.52K).

Compensation vs Earnings: Vinita's compensation has been consistent with company performance over the past year.

CEO

Vinita Gupta (55 yo)

10.7yrs

Tenure

₹109,200,000

Compensation

Ms. Vinita D. Gupta has been the Chief Executive Officer at Lupin Limited since September 1, 2013. Ms. Gupta serves as an Executive Director of Lupin Limited. She has been the Chairman and Chief Executive...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Vinita Gupta	CEO & Executive Director	10.7yrs	₹109.20m	0.072% ₹ 538.7m
Ramesh Swaminathan	Global CFO	4.2yrs	₹77.37m	0.00049% ₹ 3.7m
Nilesh Gupta	MD & Executive Director	no data	₹49.60m	0.22% ₹ 1.6b
Johnny Mikell	President & Global Head of Quality	5.3yrs	no data	no data
Christoph Funke	Chief Technical Operations Officer	less than a year	no data	no data
Sreeji Gopinathan	Chief Information Officer	4.6yrs	no data	no data
Shahin Fesharaki	Global Chief Scientific Officer	1.6yrs	no data	no data
Hemant Bakhru	Vice President of Investor Relations and M&A	no data	no data	no data
Sofia Mumtaz	President of Legal and Compliance of Australia	no data	no data	no data
Diana Amador-Toro	Senior Vice President of Global Compliance	2.1yrs	no data	no data
Shweta Munjal	VP and Global Head of Corporate Communications & Sustainability	3.3yrs	no data	no data
Fabrice Egros	President of Global Corporate Development & Growth Markets	2.3yrs	no data	no data

3.3yrs

Average Tenure

57yo

Average Age

Experienced Management: LUPIN's management team is considered experienced (3.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Vinita Gupta	CEO & Executive Director	no data	₹109.20m	0.072% ₹ 538.7m
Ramesh Swaminathan	Global CFO	4.2yrs	₹77.37m	0.00049% ₹ 3.7m
Nilesh Gupta	MD & Executive Director	15.6yrs	₹49.60m	0.22% ₹ 1.6b
Mark McDade	Independent Director	3.3yrs	₹1.45m	no data
Jean-Luc Belingard	Independent Non-Executive Director	8.6yrs	₹1.39m	no data
Kanwar Bir Anand	Independent Director	3.8yrs	₹1.57m	no data
Manju Gupta	Non-Executive Chairman of the Board	6.8yrs	₹1.45m	0.90% ₹ 6.8b
Punita Sinha	Independent Director	3.8yrs	₹1.65m	0.00011% ₹ 824.9k

4.2yrs

Average Tenure

68yo

Average Age

Experienced Board: LUPIN's board of directors are considered experienced (4.2 years average tenure).

Lupin Management

Management criteria checks 3/4

Key information

Recent management updates

Lupin Limited Announces Change in Management

Insufficient new directors

Lupin Limited, Annual General Meeting, Aug 03, 2023

Lupin Limited Announces Christine Mundkur Steps Down from Board of Directors, Effective January 1, 2023

Lupin Announces Resignation of Kamal K. Sharma from the Board of Directors

Lupin Limited Appoints Shahin Fesharaki as Global Chief Scientific Officer

Recent updates

Lupin Limited to Report Q4, 2024 Results on May 06, 2024

Investor Optimism Abounds Lupin Limited (NSE:LUPIN) But Growth Is Lacking

Lupin Limited Announces Change in Management

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.075% in the United States

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Price target increased by 12% to ₹1,355

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lupin Limited Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.075%

Insufficient new directors

Lupin Limited to Report Q3, 2024 Results on Feb 07, 2024

Lupin Receives Approval from U.S. FDA for Febuxostat Tablets

Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk

Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.07% in the United States

Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.2%

Lupin Limited Receives Tentative Approval from U.S. FDA for Canagliflozin Tablets

Lupin Limited Launches First Fixed-Dose Triple Combination Drug, Vilfuro-G® for COPD Management in India

Lupin Limited Receives Tentative Approval from U.S. FDA for Dapagliflozin Tablets

Price target increased by 8.2% to ₹1,067

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lupin Limited to Report Q2, 2024 Results on Nov 08, 2023

Lupin Limited Receives Tentative Approval from U.S. FDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution

Lupin Limited (BSE:500257) completed the acquisition of Ondero and Ondero - Met from Boehringer Ingelheim International GmbH.

Price target increased by 15% to ₹878

Lupin Limited Approves Dividend for the Year Ended March 31, 2023

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Lupin Limited Receives Tentative Approval from U.S. Fda for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Lupin Limited Receives EIR from U.S. FDA for its Pithampur Unit-2 Manufacturing Facility

Upcoming dividend of ₹4.00 per share at 0.4% yield

Lupin Limited, Annual General Meeting, Aug 03, 2023

Lupin Limited Receives Approval from U.S. Fda for Cyanocobalamin Nasal Spray

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Lupin Limited Launches Thiamine Hydrochloride Injection USP in the United States

Lupin Launches Darunavir Tablets in the United States

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Third quarter 2023 earnings: Revenues in line with analyst expectations

Lupin Receives Approval from US FDA for Glycopyrrolate Injection, USP

Lupin Limited Receives Tentative Approval from U.S. FDA for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets

Lupin Limited to Report Q3, 2023 Results on Feb 09, 2023

Lupin Limited Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients

Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets

Lupin and Exeltis Announce Reimbursement Approval of NaMuscla in Spain for the Symptomatic Treatment of Myotonia in Adults with Non-Dystrophic Myotonic Disorders

Lupin Receives Approval from U.S. FDA for Fesoterodine Fumarate Extended-Release Tablets

Lupin Limited Launches Novel Fixed-Dose Triple Drug Combination Difizma® Dpi to Treat Inadequately Controlled Asthma

Lupin Limited Announces Christine Mundkur Steps Down from Board of Directors, Effective January 1, 2023

Lupin Launches Rufinamide Tablets USP in the United States

Lupin Launches Formoterol Fumarate Inhalation Solution in the United States

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lupin Receives Tentative Approval from U.S. FDA for Doxycycline Capsules

Lupin Limited Receives Tentative Approval from U.S. FDA for Drospirenone Tablets

Lupin Limited Update on its Biotech Manufacturing Facility

Lupin Announces Resignation of Kamal K. Sharma from the Board of Directors

Lupin Limited Appoints Shahin Fesharaki as Global Chief Scientific Officer

Lupin Receives Approval from U.S. FDA for Mirabegron Extended-Release Tablets

Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w

Lupin Receives Health Canada Approval for Rymti® (Biosimilar Etanercept)

Lupin Launches Generic Suprep® Bowel Prep Kit in the United States

Lupin Limited in Partnership with Pharmascience Inc. Receives Tentative Approval from U.S. Fda for Dasatinib Tablets

Lupin Limited Announces Launch of Desvenlafaxine Extended-Release Tablets, 25 Mg

Lupin Limited (BSE:500257) agreed to acquire Ondero and Ondero - Met from Boehringer Ingelheim International GmbH for €26 million.

Lupin Limited Receives Approval from U.S. FDA for Rufinamide Tablets USP

Lupin Limited Receives Approval from U.S. FDA for Meclizine Hydrochloride Tablets USP

Lupin Limited Declares Dividend for the Year Ended March 31, 2022

Lupin Limited Receives Approval from the United States Food and Drug Administration for Its Abbreviated New Drug Application

Lupin Limited to Report Q1, 2023 Results on Aug 03, 2022